News Daily News Andexanet Alfa, Reversal Agent for Factor Xa Inhibitors, Boosts Hemostasis Todd Neale June 05, 2023
News Daily News Go With NOACs Over Warfarin in Most Cases: Updated A-fib Guidelines Todd Neale January 29, 2019
News Daily News Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval Todd Neale May 04, 2018
News Daily News Dabigatran Reversal Agent Yields No Surprises in Final RE-VERSE AD Study Results Todd Neale July 14, 2017
News Daily News FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors Michael O'Riordan August 18, 2016
News Daily News First NOAC Antidote, Idarucizumab, Approved; Likely Won’t Hold Up Interventions Todd Neale October 26, 2015
News Daily News Aprobado el Idarucizumab, Primer Antídoto de NOAC; El Deseo es no Demorar las Intervenciones Todd Neale October 26, 2015
News Daily News RE-VERSE AD: El Antídoto de Dabigatran, Seguro y Eficaz en un Análisis Provisional June 25, 2015
News Daily News RE-VERSE AD: Dabigatran Antidote Appears Safe, Effective in Interim Analysis June 25, 2015